Rapidly increasing numbers of monkeypox virus infections are occurring on at least four continents. To limit the outbreak, rapid and consistent action is required. What is particularly important is target group-specific education and information (“awareness”), isolation of cases of infection, quarantine for close contacts and suspected cases, and risk minimization in interpersonal contacts. It must be quickly evaluated whether and how a vaccination can help limit the outbreak. Approved therapeutics should be made available for potentially severe disease courses.
background
Since the first case of monkeypox was diagnosed in London, additional cases have been added in rapid succession on four continents. The first case was diagnosed in Germany on May 19, 2022, and around 250 confirmed cases worldwide had been reported to the World Health Organization ( WHO ) by May 24, 2022.
So far, the infections have mainly occurred in younger men who reported having sex with men, but there have also been intra-familial transmissions.
In keeping with the poxvirus that comes from West Africa, the clinical course of the disease has so far been relatively mild. The transmission route is assumed to be direct skin or mucous membrane contact or droplet infection. The current infection situation is dynamic with increasing case numbers. Assessing the extent of the outbreak and tracing contact chains is challenging due to the long incubation period of 1 to 3 weeks.
Problem statement
To effectively contain the global outbreak, break the chains of infection and prevent entry into the animal kingdom outside of known endemic areas, decisive, rapid and coordinated action is required.
Proposed measures
1) Outbreak management through non-pharmacological interventions
Due to the currently observed direct transmission from person to person, target group-specific and life-world-accepting education and information (“awareness” among those potentially affected and medical staff) is crucial
meaning too. In particular, people who have not been vaccinated against smallpox without a vaccination certificate or vaccination scars should avoid contact with changing sexual partners or sharing beds and clothing.
Those who are confirmed to be infected should remain in effective isolation for a period of 21 days. Inpatient hospital treatment solely for isolation reasons is not necessary; inpatient admissions should primarily be made for medical reasons in the event of severe clinical courses or impending complications.
Contact persons with a relevant risk of infection and suspected cases should go into quarantine during the incubation period or until the infection has been reliably ruled out.
Medical staff should wear suitable protective clothing (mask, gloves, gown) when caring for the above-mentioned groups of people.
2) Vaccinations
A non-replicative smallpox vaccine (MVA-BN) is approved in the EU to protect against smallpox infections (variola major, orthopoxvirus) in adults. Based on animal data, this vaccine is also approved for the prevention of monkeypox in the United States and Canada. Clinical efficacy data in humans could not be sufficiently collected due to only sporadic cases of infection so far. A corresponding study has been running for some time. Data on tolerability are available, safety data and dosage recommendations in risk groups are available.
In birth cohorts not vaccinated against smallpox (e.g. birth cohorts from the early 1970s onwards), vaccination could make a relevant contribution to increasing protection against infection and disease. Particularly in the area of known infection clusters, vaccination could prevent infections or mitigate the course of the disease and significantly limit outbreaks.
This option should be examined promptly by the EMA (EU approval) and the STIKO (vaccination recommendation). At the same time, the availability should be checked and the procurement of vaccines in sufficient quantities as well as the organization and feasibility of vaccination recommendations should be prepared. Established infectious disease treatment centers and the public health service must be provided for possible implementation.
3) Examination of therapeutic options
Although the cases to date are characterized by a known mild course of the West African monkeypox virus infection, therapeutic options should be available for vulnerable patient populations (e.g. relevant immunodeficiency). Tecovirimat, an antiviral drug, is currently approved in the EU for the treatment of monkeypox infection; an alternative is the unapproved antiviral drug brincidofovir. Availability of both must be ensured. Treatment should also take place via established infectious disease treatment centers.
This might also be of interest: Is a monkey virus in the AstraZeneca vaccine supposed to cause monkeypox?
Goodness… Source: German Health Portal
If you enjoyed this post and value the importance of well-founded information, become part of the exclusive Mimikama Club! Support our work and help us promote awareness and combat misinformation. As a club member you receive:
📬 Special Weekly Newsletter: Get exclusive content straight to your inbox.
🎥 Exclusive video* “Fact Checker Basic Course”: Learn from Andre Wolf how to recognize and combat misinformation.
📅 Early access to in-depth articles and fact checks: always be one step ahead.
📄 Bonus articles, just for you: Discover content you won't find anywhere else.
📝 Participation in webinars and workshops : Join us live or watch the recordings.
✔️ Quality exchange: Discuss safely in our comment function without trolls and bots.
Join us and become part of a community that stands for truth and clarity. Together we can make the world a little better!
* In this special course, Andre Wolf will teach you how to recognize and effectively combat misinformation. After completing the video, you have the opportunity to join our research team and actively participate in the education - an opportunity that is exclusively reserved for our club members!
Notes:
1) This content reflects the current state of affairs at the time of publication. The reproduction of individual images, screenshots, embeds or video sequences serves to discuss the topic. 2) Individual contributions were created through the use of machine assistance and were carefully checked by the Mimikama editorial team before publication. ( Reason )

